Executive Vice President
Craig Knox is an executive vice president at HM Science, a specialized division of Hughes Marino, where he represents biotech, diagnostic, medical device, and healthcare companies exclusively in their leasing and space acquisitions. Craig is an insightful advisor and aggressive advocate with a unique background in product and business development, top tier educational credentials, and deep involvement in the local business community. Prior to entering the commercial real estate industry, Craig began his career as a product design engineer and has also served as a senior manager in several public and venture-backed private companies in San Diego and the Bay Area, one of which was a spin-out from Stanford University where he received two master’s degrees. His strategic planning, financial analysis and negotiation skills developed in company management are a unique asset in serving clients in their corporate real estate matters.
Craig is a San Diego native with deep knowledge of the local market having represented hundreds of life science companies on their real estate matters and is part of HM Science’s national team representing life science companies on a global level.
Selected public company client representations include:
- QuidelOrtho Corporation – 31,000 SF, 73,000 SF (acquisition), 106,000 SF (cold storage), 180,000 SF (cGMP) & 325,000 SF (sale-lease back)
- Fate Therapeutics – 198,880 SF, 72,121 SF, 30,765 SF, 15,815 SF & 7,841 SF
- Bionano Genomics – 41,101 SF, 11,978 SF & 9,710 SF
- Ambrx – 6,700 SF & 36,000 SF
- GenMark Diagnostics/Roche – 73,057 SF, 53,347 SF & 33,908 SF
- Gossamer Bio – 64,000 SF
- Imagion Biosystems – 5,400 SF & 14,000 SF
- Synthorix (acquired by Sanofi) – 7,000 SF
- Senomyx (acquired by Firmenich) – 64,000 SF
- Xeris Pharmaceuticals – 17,105 SF
Selected venture-capital backed company client representations include:
- Aspen Neurosciences – 21,746 SF, 11,041 SF, 11,121 SF & 8,629 SF
- Vividion Therapeutics (acquired by Bayer AG) – 83,354 SF
- Artiva Biotherapeutics – 51,621 SF
- Abide Therapeutics (acquired by Lundbeck) – 17,403 SF
- Belharra Therapeutics – 20,475 SF & 16,153 SF
- Cibus – 53,423 SF, 31,939 SF & 6,207 SF
- Genalyte – 2,800 SF, 8,000 SF, 25,000 SF & 29,000 SF
- Calidi Bio – 15,000 SF
- Element Biosciences – 14,000 SF, 16,000 SF, 21,000 SF & 186,000 SF
- Nucleix – 7,400 SF
- Janux Therapeutics – 7,400 SF and 47,000 SF
- Carlsmed – 16,000 SF
- Neuvogen – 8,000 SF
- Verogen – 12,000 SF
- ViaCyte (acquired by Vertex) – 10,000 SF (disposition), 18,000 SF, 32,000 SF
- Truvian Sciences – 10,000 SF & 34,000 SF
- Orco Biosystems – 94,000 SF (cGMP)
Selected non-profit research institute representations include:
- EvoNexus – 11,000 SF
- Lowy Medical Research Institute – 3,400 SF
- La Jolla Bioengineering Institute – 12,000 SF
Prior to Hughes Marino, Craig was vice president of business development and client services for the law firm of Cooley LLP in San Diego. Craig has served as a board member for numerous San Diego community organizations over the past several decades including the EvoNexus start-up incubator, UCSD Cancer Center Longboard Invitational & Luau which has raised over $10 million for cancer research, the Magdalena Ecke YMCA board of directors, Del Mar Schools Education Foundation, and Board of Elders of Grace Point Church.
Craig received a Masters of Business Administration from Stanford’s Graduate School of Business and a Masters of Manufacturing Systems Engineering from Stanford University where he received a fellowship from the Stanford Integrated Manufacturing Association (SIMA). He holds a Bachelor of Science in Mechanical Engineering from San Diego State University where he graduated magna cum laude.
Craig is an avid surfer in San Diego’s North County, where he resides with his wife and four children.